| Literature DB >> 35386862 |
Abdullah A Alharbi1, Khalid I Alqumaizi2, Ibrahim Bin Hussain3,4,5, Abdullah Alsabaani6, Amr Arkoubi7, Abdulaziz Alkaabba8, Arwa AlHazmi5, Nasser S Alharbi9, Hussam M Suhail10, Abdullah K Alqumaizi11.
Abstract
Background: This is the first descriptive and comparative study conducted of COVID-19 inpatients from multi-centers in the four administrative southern regions and proposed Southern Business Unit (Jazan, Najran, Bisha, and Aseer) of the Kingdom of Saudi Arabia (KSA).Entities:
Keywords: COVID-19; Saudi Arabia; Southern Business Unit; clinical course, outcomes, and complications; demographic and clinical characteristics; inpatient characteristics
Year: 2022 PMID: 35386862 PMCID: PMC8979417 DOI: 10.2147/IJGM.S357552
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Demographic and Clinical Characteristics of COVID-19 Inpatients by Regions in Southern KSA
| Characteristics | Frequency (n and %) | Chi-Square or #One Way ANOVA | ||||
|---|---|---|---|---|---|---|
| Total N (%) | Jazan n (%) | Najran n (%) | Bisha n (%) | Aseer n (%) | ||
| Population | 809 (100%) | 98 (12%) | 120 (15%) | 267 (33%) | 324 (40%) | |
| Age (>17 years) mean (SD) | 60.0 (±17.6) | 56.5 (±17.3) | 63.5 (±18.6) | 59.7 (±17.8) | 60.1 (±17.2) | 0.020#* |
| Gender | ||||||
| Male | 576 (71.0%) | 72 (73.0%) | 79 (66.0%) | 182 (68.0%) | 243 (75.0%) | 0.144 |
| Female | 233 (29.0%) | 26 (27.0%) | 41 (34.0%) | 85 (32.0%) | 81 (25.0%) | |
| Nationality | ||||||
| Non-Saudi | 234 (29.0%) | 36 (37.0%) | 43 (36%) | 58 (22%) | 97 (30%) | 0.006** |
| Saudi | 575 (71.0%) | 62 (63.0%) | 77 (64%) | 209 (78%) | 227 (70%) | |
| Diabetes | ||||||
| No | 342 (42.0%) | 55 (56.0%) | 43 (36.0%) | 122 (46.0%) | 122 (38.0%) | 0.003** |
| Yes | 467 (58.0%) | 43 (44.0%) | 77 (64.0%) | 145 (54.0%) | 202 (62.0%) | |
| Hypertension | ||||||
| No | 426 (53.0%) | 56 (57.0%) | 56 (47.0%) | 155 (58.0%) | 159 (49.0%) | 0.063 |
| Yes | 383 (47.0%) | 43 (43.0%) | 64 (53.0%) | 112 (42.0%) | 165 (51.0%) | |
| Obesity | ||||||
| No | 462 (57.0%) | 68 (69.0%) | 61 (51.0%) | 180 (67.0%) | 153 (47.0%) | <0.001*** |
| Yes | 347 (43.0%) | 30 (31.0%) | 59 (49.0%) | 87 (33.0%) | 171 (53.0%) | |
| Cardiac diseases | ||||||
| No | 688 (85.0%) | 85 (87.0%) | 83 (69.0%) | 236 (88.0%) | 284 (88.0%) | <0.001*** |
| Yes | 121 (15.0%) | 13 (13.0%) | 37 (31.0%) | 31 (12.0%) | 40 (12.0%) | |
| Immunocompromised | ||||||
| No | 797 (98.5%) | 91 (92.0%) | 117 (97.5%) | 267 (100.0%) | 322 (99.0%) | <0.001*** |
| Yes | 12 (1.50%) | 7 (8.0%) | 3 (2.5%) | 0 (0.0%) | 2 (1.0%) | |
| History of cancer | ||||||
| No | 802 (99.0%) | 98 (100.0%) | 120 (100.0%) | 263 (98.5%) | 321 (99.0%) | 0.367 |
| Yes | 7 (1.0%) | 0. (0.0%) | 0 (0.0%) | 4 (1.5%) | 3 (1.0%) | |
Notes: Results were offered as frequency (number (n) and percent (%)). Correlation between variables was evaluated using the chi-square test. *Significant difference at p ≤ 0.05, **significant difference at p ≤ 0.01, and ***significant difference at p ≤ 0.001; #p. value based on One Way ANOVA test for continuous variables.
Clinical Course, Outcomes, and Complications of COVID-19 Inpatients by Regions in Southern KSA
| Characteristics | Frequency (n and %) | Chi-Square or #One Way ANOVA | ||||
|---|---|---|---|---|---|---|
| Total N (%) | Jazan N (%) | Najran N (%) | Bisha N (%) | Aseer N (%) | ||
| 809 (100%) | 98 (12%) | 120 (15%) | 267 (33%) | 324 (40%) | ||
| Stage at admission | ||||||
| Stage A | 255 (31.0%) | 38 (39.0%) | 40 (33.0%) | 41 (15.0%) | 136 (42.0%) | <0.001*** |
| Stage B | 450 (56.0%) | 47 (48.0%) | 67 (56.0%) | 214 (80.0%) | 122 (38.0%) | |
| Stage C | 104 (13.0%) | 13 (13.0%) | 13 (11.0%) | 12 (5.0%) | 66 (20.0%) | |
| Discharge home | ||||||
| No | 277 (34.0%) | 32 (33.0%) | 66 (55.0%) | 42 (16.0%) | 137 (42.0%) | <0.001*** |
| Yes | 532 (66.0%) | 66 (67.0%) | 54 (45.0%) | 225 (84.0%) | 187 (56.0%) | |
| Refer to another facility | ||||||
| No | 736 (91.0%) | 94 (96.0%) | 101 (84.0%) | 266 (99.6%) | 275 (85.0%) | <0.001*** |
| Yes | 73 (9.0%) | 4 (4.0%) | 19 (16.0%) | 1 (0.4%) | 49 (15.0%) | |
| Death in hospital | ||||||
| No | 609 (75.0%) | 72 (73.0%) | 73 (61.0%) | 226 (85.0%) | 238 (73.0%) | <0.001*** |
| Yes | 200 (25.0%) | 26 (27.0%) | 47 (39.0%) | 41 (15.0%) | 86 (27.0%) | |
| ICU admission | ||||||
| No | 387 (48.0%) | 59 (60.0%) | 40 (33.0%) | 184 (69.0%) | 104 (32.0%) | <0.001*** |
| Yes | 422 (52.0%) | 39 (40.0%) | 80 (67.0%) | 83 (31.0%) | 220 (68.0%) | |
| Duration of stay in days, mean (SD) | 11.1 (±9.5) | 10.54 (±7.5) | 15.1 (±9.6) | 7.30 (±8.6) | 13.00 (±9.8) | <0.001#*** |
| Sepsis | ||||||
| No | 648 (80.0%) | 81 (83.0%) | 84 (70.0%) | 236 (88.0%) | 247 (76.0%) | <0.001*** |
| Yes | 161 (20.0%) | 17 (17.0%) | 36 (30.0%) | 31 (12.0%) | 77 (24.0%) | |
| Bacterial pneumonia | ||||||
| No | 286 (35.0%) | 85 (87.0%) | 42 (35.0%) | 8 (3.0%) | 151 (47.0%) | <0.001*** |
| Yes | 523 (65.0%) | 13 (13.0%) | 78 (65.0%) | 259 (97.0%) | 173 (53.0%) | |
| ARDS | ||||||
| No | 554 (68.0%) | 67 (68.0%) | 67 (56.0%) | 222 (83.0%) | 198 (61.0%) | <0.001*** |
| Yes | 255 (32.0%) | 31 (32.0%) | 53 (44.0%) | 45 (17.0%) | 126 (39.0%) | |
| Arrythmia | ||||||
| No | 774 (96.0%) | 93 (95.0%) | 98 (82.0%) | 261 (98.0%) | 321 (99.0%) | <0.001*** |
| Yes | 35 (4.0%) | 5 (5.0%) | 22 (18.0%) | 6 (2.0%) | 3 (1.0%) | |
| Acute kidney injury | ||||||
| No | 691 (85.0%) | 86 (88.0%) | 95 (79.0%) | 247 (93.0%) | 263 (81.0%) | <0.001*** |
| Yes | 118 (15.0%) | 12 (12.0%) | 25 (21.0%) | 20 (7.0%) | 61 (19.0%) | |
| Hepatotoxicity | ||||||
| No | 795 (98.0%) | 94 (96.0%) | 116 (97.0%) | 265 (99.0%) | 320 (99.0%) | 0.073 |
| Yes | 14 (2.0%) | 4 (4.0%) | 4 (3.0%) | 2 (1.0%) | 4 (1.0%) | |
| GIT perforation | ||||||
| No | 803 (99.0%) | 97 (99.0%) | 117 (97.0%) | 367 (100.0%) | 322 (99.0%) | 0.066 |
| Yes | 6 (1.0%) | 1 (1.0%) | 3 (3.0%) | 0 (0.0%) | 2 (1.0%) | |
| Multi-organ failure | ||||||
| No | 666 (82.0%) | 91 (93.0%) | 96 (80.0%) | 247 (93.0%) | 232 (72.0%) | <0.001*** |
| Yes | 143 (18.0%) | 7 (7.0%) | 24 (20.0%) | 20 (7.0%) | 92 (28.0%) | |
Notes: Results were offered as frequency (number (n) and percent (%)). Correlation between variables was evaluated using the chi-square test. ***Significant difference at p ≤ 0.001; #p. value based on one way ANOVA test for continuous variables.